Tag
This pooled analysis of INTERACT and ATACH-II trials reveals that intensive blood pressure lowering significantly improves outcomes only in patients with deep intracerebral hemorrhage, highlighting hematoma location as crucial for personali
Iatrogenic cerebral amyloid angiopathy (iCAA) exhibits high symptomatic intracerebral hemorrhage rates decades after exposure. This analysis of 82 European cases highlights recurrence risks and cognitive outcomes, informing prognosis and pa
Cilostazol promotes dural lymphatic remodeling and hematoma clearance post-ICH without increasing bleeding risk, representing a promising therapeutic strategy to improve neurological outcomes.
DWI-positive lesions in acute intracerebral hemorrhage patients correlate with cerebral small vessel disease markers and predict poorer 6-month outcomes, with lesion distribution varying by small vessel disease subtype.
The STATICH trial assessed safety and efficacy of antiplatelet therapy after intracerebral hemorrhage, revealing increased hemorrhagic risk but fewer ischemic events among treated patients, highlighting ongoing clinical dilemmas.
This pilot randomized trial demonstrates the feasibility of using low-dose colchicine after acute intracerebral hemorrhage to prevent vascular events, highlighting considerations for future larger studies regarding recruitment, adherence, a
A secondary analysis of the INTERACT3 trial shows that younger adults (≤50 years) with intracerebral hemorrhage have lower mortality and disability but differ in risk factors and may benefit more from bundled care.
Mobile Stroke Units enable faster diagnosis and initiation of antihypertensive treatment in intracerebral hemorrhage, significantly reducing time to care compared with conventional EMS transportation.
A pooled analysis of 11,269 patients from the INTERACT and ATACH-II trials reveals that 24-hour systolic blood pressure trajectories, rather than just single targets, significantly influence functional outcomes after intracerebral hemorrhag
This article synthesizes evidence from a large-scale individual participant data meta-analysis, demonstrating that early perihematomal edema growth (at 24 and 72 hours) is an independent predictor of death and disability after intracerebral
While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectori
A post hoc analysis of the SWITCH trial demonstrates that the clinical benefits of decompressive craniectomy in reducing death and severe disability are consistent across different anatomical locations of deep supratentorial intracerebral h
A pooled analysis of over 11,000 patients from the INTERACT trials demonstrates that intensive blood pressure reduction significantly improves functional recovery in acute intracerebral hemorrhage, with the most robust benefits observed whe
This article explores how gut microbiota dysbiosis and NLRP3 inflammasome activation contribute to secondary white matter injury post-intracerebral hemorrhage, outlining mechanisms and potential therapeutic strategies.
The MIND trial compared minimally invasive surgery using the Artemis device to standard medical management for supratentorial intracerebral hemorrhage, finding no significant improvement in 180-day functional outcomes or 30-day mortality wi
The MIND trial found no significant functional benefit or mortality reduction with minimally invasive surgery compared to medical management alone in supratentorial intracerebral hemorrhage patients at 180 days.
Mediation analysis of INTERACT3 reveals that systolic blood pressure and blood glucose control are primary drivers of functional recovery benefits in acute intracerebral hemorrhage care bundles.
